Is there any concern from an INCY standpoint of IOmet having dual IDO/TDO inhibitors? Presumably MRK could favor these way down the road over the INCY drug, which I believe is just an IDO inhibitor. Any more guidance if it's more beneficial to inhibit both targets rather than IDO alone? Guessing just way too early to know.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.